Department of Obstetrics and Gynecology, The First Affiliated Hospital of Xi'an Jiaotong University, Shaanxi, China.
Acta Obstet Gynecol Scand. 2024 Apr;103(4):636-644. doi: 10.1111/aogs.14789. Epub 2024 Jan 28.
Gestational trophoblastic neoplasia (GTN) is a highly invasive tumor, mainly spreading to the lungs. However, lung metastasis in GTN is usually not considered as an adverse prognostic factor. Therefore, the aim of this study was to summarize the results of previous studies and evaluate the effects of lung metastasis on the treatment and prognosis of GTN.
The study was prospectively registered in PROSPERO (CRD42023372371). Electronic databases including PubMed, Embase, the Cochrane Library, Chinese National Knowledge Infrastructure, Wanfang, and China Biomedical Literature Database were used for a systematical search of relevant studies published up to November 21, 2022. The observational studies reporting the clinical outcomes of GTN patients with and without lung metastasis were selected. The incidences of resistance, relapse, and mortality of GTN patients were extracted and successively grouped based on the presence of lung metastasis. The pooled relative risks (RRs) and 95% confidence interval (95% CI) of the eligible studies were calculated. The qualities of included studies were assessed with the Newcastle-Ottawa Scale and the certainty of evidence was graded based on the GRADE. The meta-analysis was performed using Stata 12.0 and GradePro software.
Five publications with 3629 GTN patients were included. The meta-analysis revealed that the GTN with lung metastasis was strongly correlated with first-line chemoresistance (pooled RR = 1.40, 95% CI: 1.22 to 1.61, p < 0.001), recurrence (pooled RR = 3.03, 95% CI: 1.21 to 7.62, p = 0.018), and disease-specific death (pooled RR = 22.11, 95% CI: 3.37 to 145.08, p = 0.001). Ethnicity was also an important factor and Caucasian GTN patients with lung metastasis showed a higher risk of recurrence as revealed by the subgroup analysis (pooled RR = 5.10, 95% CI: 2.38 to 10.94, p < 0.001).
GTN patients with lung metastasis exhibited a higher risk of chemoresistance, relapse, and disease-specific death. Patients with lung metastasis among the Caucasian population had a higher risk of recurrence than Asian populations. Therefore, the presence of lung metastases might be considered as a high-risk factor for prognosis of GTN and deserves more attention in the choice of first-line chemotherapy regimens and follow-up.
滋养细胞肿瘤(GTN)是一种高度侵袭性肿瘤,主要向肺部扩散。然而,GTN 的肺转移通常不被认为是预后不良的因素。因此,本研究旨在总结以往研究的结果,并评估肺转移对 GTN 治疗和预后的影响。
本研究前瞻性地在 PROSPERO(CRD42023372371)注册。使用电子数据库(包括 PubMed、Embase、Cochrane 图书馆、中国国家知识基础设施、万方和中国生物医学文献数据库)对截至 2022 年 11 月 21 日发表的相关研究进行系统检索。选择报告 GTN 患者有和无肺转移的临床结局的观察性研究。提取 GTN 患者耐药、复发和死亡的发生率,并根据是否存在肺转移进行分组。使用 Stata 12.0 和 GradePro 软件计算合格研究的汇总相对风险(RR)和 95%置信区间(95%CI)。使用纽卡斯尔-渥太华量表评估纳入研究的质量,并根据 GRADE 分级评估证据的确定性。
纳入了 5 篇文献,共 3629 例 GTN 患者。Meta 分析显示,GTN 伴肺转移与一线化疗耐药(汇总 RR=1.40,95%CI:1.22 至 1.61,p<0.001)、复发(汇总 RR=3.03,95%CI:1.21 至 7.62,p=0.018)和疾病特异性死亡(汇总 RR=22.11,95%CI:3.37 至 145.08,p=0.001)密切相关。种族也是一个重要因素,亚组分析显示,白人 GTN 患者伴肺转移的复发风险更高(汇总 RR=5.10,95%CI:2.38 至 10.94,p<0.001)。
GTN 伴肺转移患者化疗耐药、复发和疾病特异性死亡的风险更高。与亚洲人群相比,白人 GTN 伴肺转移患者的复发风险更高。因此,肺转移的存在可能被视为 GTN 预后的高危因素,在一线化疗方案的选择和随访中值得更多关注。